Q3 2025 EPS Estimates for Lifecore Biomedical, Inc. (NASDAQ:LFCR) Lifted by Barrington Research

Lifecore Biomedical, Inc. (NASDAQ:LFCR) – Analysts at Barrington Research boosted their Q3 2025 earnings estimates for shares of Lifecore Biomedical in a research report issued on Monday, October 7th. Barrington Research analyst M. Petusky now anticipates that the company will post earnings per share of ($0.16) for the quarter, up from their prior estimate of ($0.17). Barrington Research has a “Market Perform” rating on the stock. The consensus estimate for Lifecore Biomedical’s current full-year earnings is ($0.89) per share. Barrington Research also issued estimates for Lifecore Biomedical’s Q4 2025 earnings at $0.01 EPS and FY2025 earnings at ($0.94) EPS.

Lifecore Biomedical (NASDAQ:LFCR) last announced its quarterly earnings data on Monday, August 26th. The company reported ($0.15) earnings per share (EPS) for the quarter. The business had revenue of $37.89 million for the quarter. Lifecore Biomedical had a net margin of 9.37% and a negative return on equity of 515.12%.

Separately, Craig Hallum assumed coverage on Lifecore Biomedical in a report on Thursday, September 5th. They issued a “buy” rating and a $8.00 target price for the company.

Lifecore Biomedical Price Performance

LFCR stock opened at $4.81 on Wednesday. Lifecore Biomedical has a 1 year low of $3.68 and a 1 year high of $8.90. The company has a debt-to-equity ratio of 12.90, a current ratio of 2.08 and a quick ratio of 1.06. The firm has a market capitalization of $145.85 million, a PE ratio of -1.44 and a beta of 0.95. The business has a 50 day simple moving average of $5.13 and a 200-day simple moving average of $5.52.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of LFCR. Allegheny Financial Group LTD acquired a new stake in shares of Lifecore Biomedical in the second quarter valued at $52,000. SG Americas Securities LLC purchased a new position in shares of Lifecore Biomedical in the first quarter valued at approximately $57,000. Mirae Asset Global Investments Co. Ltd. acquired a new position in shares of Lifecore Biomedical in the first quarter valued at approximately $58,000. Renaissance Technologies LLC purchased a new stake in Lifecore Biomedical during the 2nd quarter worth approximately $56,000. Finally, Boston Partners acquired a new stake in Lifecore Biomedical during the 1st quarter worth approximately $104,000. Institutional investors and hedge funds own 83.36% of the company’s stock.

Insiders Place Their Bets

In other Lifecore Biomedical news, major shareholder Wynnefield Partners Small Cap acquired 122,930 shares of the firm’s stock in a transaction that occurred on Thursday, October 3rd. The shares were purchased at an average cost of $4.10 per share, for a total transaction of $504,013.00. Following the completion of the acquisition, the insider now owns 2,095,783 shares of the company’s stock, valued at approximately $8,592,710.30. The trade was a 0.00 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at this hyperlink. 14.61% of the stock is owned by insiders.

Lifecore Biomedical Company Profile

Lifecore Biomedical, Inc, together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures.